会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • CONTINUOUS SPRAY-CAPTURE PRODUCTION SYSTEM
    • 连续喷雾生产系统
    • WO2007084500A3
    • 2007-11-15
    • PCT/US2007001126
    • 2007-01-16
    • ADVANCED BIONUTRITION CORPPIECHOCKI JOHNKYLE DAVID J
    • PIECHOCKI JOHNKYLE DAVID J
    • A01N43/04C08L3/00
    • C08J3/03C08B37/0084C08J3/075C08J3/122C08J3/24C08J2303/02C08J2305/04C08L3/02C08L5/04
    • The disclosure relates to novel microencapsulation processes based on the use of high viscosity fluids (e.g., gelatinized starch and alginate), which are mixed and then sprayed using a much gentler hydraulic pressure and, preferably gas-based atomization into a crosslinking solution (e.g.. of calcium chloride). To improve the efficiency of the system, the process can be performed in a continuous mode rather than by a conventional batch process. This involves continuous or intermittent harvest of the microparticles collected in the capture vessel followed by amendment and recycling of the CaCl 2 solution and its redeployment into the capture vessel. The process allows production of microencapsulated probiotic bacteria without major losses in viability, thereby providing a useful and efficient new manufacturing method for the stabilization of probiotic bacteria prior to their introduction into functional foods.
    • 本公开涉及基于使用高粘度流体(例如糊化淀粉和藻酸盐)的新型微胶囊化方法,所述新型微胶囊化方法被混合,然后使用较轻的液压进行喷雾,并且优选基于气体雾化进入交联溶液(例如, 的氯化钙)。 为了提高系统的效率,该过程可以以连续模式而不是常规的批处理进行。 这涉及收集在捕获容器中的微粒的连续或间歇收获,随后修复和回收CaCl 2 O 2溶液及其再次部署到捕获容器中。 该方法允许生产微胶囊化的益生菌,而不会在生存力方面造成重大损失,从而为在益生菌引入功能性食品之前稳定益生菌提供了有用和高效的新的制造方法。
    • 8. 发明申请
    • THERAPEUTIC PREPARATIONS OF HIGHLY UNSATURATED FATTY ACIDS
    • 高度不饱和脂肪酸的治疗方法
    • WO0149282A3
    • 2002-04-04
    • PCT/US0100507
    • 2001-01-08
    • MARTEK BIOSCIENCES CORPKYLE DAVID J
    • KYLE DAVID J
    • A61K31/20A61K31/23A61K35/70A61K35/80A61P25/00A61P43/00
    • A61K31/20A61K31/23
    • This invention provides a therapeutic composition comprising highly unsaturated fatty acids (HUFAs) in an amount and form sufficient to produce normal or supernormal levels of one or more of the respective HUFAs in one or more tissues of an individual in need thereof upon administration of the composition. Preferably, administration of this composition will raise the tissue level of one or more HUFA to over twice normal in a target tissue, more preferably, the tissue level of DHA is raised to over twice normal in the target tissue. Typically, the individual in need of the therapeutic composition is a mammal, especially a human, suffering from a disease selected from the group consisting of cystic fibrosis, multiple sclerosis, cerebral palsy, amyotrophic lateral sclerosis, phenylketonuria, and neurological disorders, including certain neurodegenerative diseases and psychiatric disorders. Preferably, the levels of one or more of the respective HUFAs, especially DHA, are normalized or supernormalized in membranes of the individual. In another preferred mode of this invention, the HUFAs in the therapeutic composition are in a readily absorbable form, such that the dose of HUFA required to achieve normal or supernormal levels in the individual is lower than the dose required for HUFA-containing triglycerides. For example, the HUFAs may be predominantely in the form of glycerol esters. Preferably at least 70% of the HUFAs are esterified to glycerol; more preferably, the HUFAs are predominantely in the form of diglycerides and/or monoglycerides.
    • 本发明提供包含高度不饱和脂肪酸(HUFA)的治疗组合物,其量和形式足以在施用组合物时产生有需要的个体的一个或多个组织中的一种或多种相应HUFA的正常或超常水平 。 优选地,该组合物的施用将使靶组织中的一种或多种HUFA的组织水平升高到正常的两倍以上,更优选地,目标组织中DHA的组织水平升高到正常的两倍以上。 通常,需要治疗组合物的个体是患有选自囊性纤维化,多发性硬化,脑性麻痹,肌萎缩性侧索硬化,苯丙酮尿症和神经系统疾病(包括某些神经变性)的疾病的哺乳动物,特别是人 疾病和精神疾病。 优选地,各个HUFA,特别是DHA中的一种或多种的水平在个体的膜中被标准化或超正规化。 在本发明的另一优选方式中,治疗组合物中的HUFA是易于吸收的形式,使得在个体中达到正常或超常量水平所需的HUFA剂量低于含有HUFA的甘油三酸酯所需的剂量。 例如,HUFA可以主要以甘油酯的形式存在。 优选地,至少70%的HUFA被酯化成甘油; 更优选地,HUFA主要是甘油二酯和/或甘油单酯的形式。